Mercury Laboratories Ltd.

As of June 30, 2026, Mercury Laboratories Ltd. carries a market capitalization of 944.04M, placing it among publicly traded companies globally. Its enterprise value stands at 944.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Mercury Laboratories Ltd. has 1.20M shares outstanding.

As of June 30, 2026, Mercury Laboratories Ltd. trades at a trailing price-to-earnings ratio of 22.68.

As of June 30, 2026, Mercury Laboratories Ltd. trades at an EV/EBITDA multiple of 12.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.59 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 944.04M versus a market cap of 944.04M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 1.46M in revenue per employee across its workforce of 506.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Mercury Laboratories Ltd. recorded 13.18M in income tax expense. That works out to an effective tax rate of 24.04, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 54.82M, leaving 41.64M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Mercury Laboratories Ltd.'s stock has declined approximately 17.71% over the past 52 weeks. The 50-day moving average sits at 774.86, while the 200-day moving average is 794.92.

Over the twelve months ended June 30, 2026, Mercury Laboratories Ltd. generated 737.65M in revenue and converted that into 41.64M in net income, yielding earnings per share of 34.69. EBITDA reached 74.84M, while operating income came in at 45.73M.

Over the twelve months ended June 30, 2026, Mercury Laboratories Ltd. posted a gross margin of 61.54, reflecting its pricing power and cost economics. The operating margin of 6.20 and net profit margin of 5.64 provide insight into operational efficiency.